Director/PDMR Shareholding
Updated : 15:18
24 October 2018
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Dechra Pharmaceuticals PLC announces that on 22 October 2018, the following PDMRs exercised nil cost options over ordinary shares of 1p each in the Company. The options were granted to them on 15 September 2015 pursuant to the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP). The exercise of the options was subject to the achievement of performance conditions which were satisfied in full so that the options vested at 100%. The PDMRs sold sufficient shares (acquired pursuant to the exercise) in order to fund the resulting tax liability.
Name | Capacity | Options Exercised | Shares Sold | Sale Price per share | Total beneficial shareholding following this announcement | Percentage of issued share capital |
Ian Page | Director | 90,721 | 42,768 | £21.395965 | 786,650 | 0.767% |
Tony Griffin | Director | 22,641 | 11,355 | £21.395965 | 75,606 | 0.074% |
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
a) | Name | Ian Page
| |
2. | Reason for the notification | ||
a) | Position/status | Director/PDMR
| |
b) | Initial notification/ amendment | Initial Notification | |
3. | Details of the Issuer | ||
a) | Name | Dechra Pharmaceuticals PLC | |
b) | LEI code | 213800J4UVB5OWG8VX82
| |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 1 pence each
ISIN: GB0009633180 | |
b) | Nature of the transaction | Exercise of 90,721 options under the Company's Long Term Incentive Plan
| |
c) | Price(s) and volumes(s) | Price(s) £Nil Cost | Volume(s) 90,721 |
d) | Aggregated information - Aggregate volume - Price |
N/A | |
e) | Date of the transaction | 2018.10.22 | |
f) | Place of the transaction | Outside a trading venue |
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
a) | Name | Ian Page
| |
2. | Reason for the notification | ||
a) | Position/status | Director/PDMR
| |
b) | Initial notification/ amendment | Initial Notification | |
3. | Details of the Issuer | ||
a) | Name | Dechra Pharmaceuticals PLC | |
b) | LEI code | 213800J4UVB5OWG8VX82
| |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 1 pence each
ISIN: GB0009633180 | |
b) | Nature of the transaction | Partial sale of shares obtained under the Company's Long Term Incentive Plan to satisfy tax liability
| |
c) | Price(s) and volumes(s) | Price(s) £21.395965 | Volume(s) 42,768 |
d) | Aggregated information - Aggregate volume - Price |
42,768
£915,062.63 | |
e) | Date of the transaction | 2018.10.23 | |
f) | Place of the transaction | London Stock Exchange |
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
a) | Name | Tony Griffin
| |
2. | Reason for the notification | ||
a) | Position/status | Director/PDMR
| |
b) | Initial notification/ amendment | Initial Notification | |
3. | Details of the Issuer | ||
a) | Name | Dechra Pharmaceuticals PLC | |
b) | LEI code | 213800J4UVB5OWG8VX82 | |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 1 pence each
ISIN: GB0009633180 | |
b) | Nature of the transaction | Exercise of 22,641 options under the Company's Long Term Incentive Plan | |
c) | Price(s) and volumes(s) | Price(s) £nil | Volume(s) 22,641 |
d) | Aggregated information - Aggregate volume - Price |
N/A | |
e) | Date of the transaction | 2018.10.22 | |
f) | Place of the transaction | Outside a trading venue |
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
a) | Name | Tony Griffin
| |
2. | Reason for the notification | ||
a) | Position/status | Director/PDMR
| |
b) | Initial notification/ amendment | Initial Notification | |
3. | Details of the Issuer | ||
a) | Name | Dechra Pharmaceuticals PLC | |
b) | LEI code | 213800J4UVB5OWG8VX82 | |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 1 pence each
ISIN: GB0009633180 | |
b) | Nature of the transaction | Partial sale of shares obtained under the Company's Long Term Incentive Plan to satisfy tax liability.
| |
c) | Price(s) and volumes(s) | Price(s) £21.395965 | Volume(s) 11,355 |
d) | Aggregated information - Aggregate volume - Price |
11,355
£242,951.18 | |
e) | Date of the transaction | 2018.10.23 | |
f) | Place of the transaction | London Stock Exchange |
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.